Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 May;125(5):610-1.
doi: 10.1164/arrd.1982.125.5.610.

Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis

Amphotericin B in Liposomes: A Novel Therapy for Histoplasmosis

R L Taylor et al. Am Rev Respir Dis. .

Abstract

Incorporation of amphotericin B into liposomes significantly altered its toxicity, tissue distribution, and efficacy. Compared with intravenously administered amphotericin B-desoxycholate, liposome-amphotericin B showed a reduced acute toxicity and a maximal tolerable dose 9 times greater than amphotericin B-desoxycholate. Liposome-amphotericin B also produced higher tissue and lower serum concentrations than amphotericin B-desoxycholate, and was significantly more effective in prolonging survival of mice infected with Histoplasma capsulatum.

Similar articles

See all similar articles

Cited by 33 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback